1. Home
  2. FOUR vs LQDA Comparison

FOUR vs LQDA Comparison

Compare FOUR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shift4 Payments Inc.

FOUR

Shift4 Payments Inc.

HOLD

Current Price

$44.48

Market Cap

3.7B

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$39.29

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOUR
LQDA
Founded
1999
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.1B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
FOUR
LQDA
Price
$44.48
$39.29
Analyst Decision
Buy
Strong Buy
Analyst Count
22
11
Target Price
$79.05
$41.00
AVG Volume (30 Days)
1.3M
966.9K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.81
EPS
N/A
N/A
Revenue
$4,180,000,000.00
$158,320,000.00
Revenue This Year
$23.83
$278.87
Revenue Next Year
$14.30
$57.13
P/E Ratio
$27.53
N/A
Revenue Growth
25.50
1031.18
52 Week Low
$39.91
$11.85
52 Week High
$107.16
$46.67

Technical Indicators

Market Signals
Indicator
FOUR
LQDA
Relative Strength Index (RSI) 44.83 56.54
Support Level $43.32 $35.00
Resistance Level $51.65 $42.00
Average True Range (ATR) 2.37 1.85
MACD -0.10 -0.07
Stochastic Oscillator 18.06 56.21

Price Performance

Historical Comparison
FOUR
LQDA

About FOUR Shift4 Payments Inc.

Shift4 Payments Inc is an independent provider of software and payment processing solutions in the U.S., expanding internationally. Its payments platform offers integrated products and services across in-store, online, mobile and tablet-based channels, including end-to-end payment processing, merchant acquiring services, a proprietary omni-channel gateway, eCommerce capabilities, and reporting tools. The company distributes its services through internal sales teams and partners, including independent software vendors (ISVs) and value-added resellers (VARs). Revenue is predominantly recurring, derived mainly from processing fees and subscription revenue from POS software, business intelligence tools and other technology solutions. The company derives maximum revenue from the United States.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: